Skip to main content Skip to search Skip to main navigation
News: EMA

EMA: Public Consultation on Remote Batch Certification

The EMA has published a four-page consultation document in the form of Q&As concerning the physical attendance and the place of a personal residence of a Qualified Person on 11 May 2022. The guidance states that the work of a QP must be adapted to current standards to enable remote certifications without a QP being present at the site. A public consultation is possible until 13 June 2022.

The Q&A is based on the fundamentals of the EU GMP Guidelines, in particular those of Annex 16, and is applicable to EU/EEA QP certification or QP confirmation. It applies to the production and importation of human and veterinary medicinal products as well as investigational medicinal products. Following is a brief summary of the four Q&As:

Is remote batch certification / batch confirmation by the QP (i.e. when not at the authorised site address specified on the MIA) allowed on a routine basis?

This could be acceptable if a remote certification is accepted by the national authority at the site. The manufacturer and the qualified person should meet all valid local requirements.


Where remote QP certification / confirmation is allowed on a routine basis, what conditions should apply?

Broadly summarised, they include

  • full compliance of the remote certification with EU legislation and EU GMP guidelines
  • a certification that must take place within the EU/EEA in any case
  • adequate documentation and control within the quality system when remote certification is used on a routine basis
  • electronic access to any information required for QP according to Annex 16 EU GMP Guidance. All IT systems must comply with the requirements of EU-GMP Annex 11
  • The availability of all performed measurements for inspection purposes by the competent authorities.

Is the QP required to be a resident in the Member State where the authorised site is located?

Reference is made to the specific national requirements


What are the technical requirements for the remote access and the signature used for batch certification / confirmation?

In terms of IT security and data integrity, the risk for remote access is higher than for access within the controlled environment at the approved site. The minimum requirements are highly dependent on the state of the technology and should be consistent with the guidelines of Annex 11. For instance, among other things:

  • Recognized industry standards should be used for authentication and authorization (e.g., two-factor or multi-factor authentication)
  • Security parameters on the network operating system, database, and application layer of the QP should be configured adequately
  • data should be secured using a high-level of transport encryption
  • the MIA holder must ensure that only the QP is able to perform remote certification/confirmation of batches

Source:

EMA: Public Consultation Concerning The Physical Attendance And The Location Of Personal Residency Of The Qualified Person

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

When outsourcing GDP activities, there is a need for concrete delimitation of responsibilities between a client and a contractor. Read more about the goals and the contents of a quality agreement in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
Question of the Week | GMP-Verlag

What are the Benefits and Limitations of Passive Temperature-Controlled Containers for Drug Transport?

Here's the answer:
Read more
FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

The FDA has updated its recommendations on Acceptable Intake (AI) limits for nitrosamine impurities. Under certain conditions, the Agency now accepts a Less-Than-Lifetime (LTL) adjustment of AI limits for medicinal products that are not intended for lifetime use. This also represents an alignment with the LTL concept of ICH M7(R2).
Read more
Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

As of 15 November 2026, active substances must be registered in the EMA's Substance Management Services (SMS) database before Swissmedic can include them in establishment licences and GMP certificates for active substance manufacturers. The new requirement results from modifications to the EudraGMDP database.
Read more
News: EMA

EMA: New Q&As for Biological Medicinal Products

The EMA has added a new section to its Q&As on biological medicinal products addressing medicinal products containing secretomes or extracellular vesicles (EVs) obtained from human or animal cells.
Read more
News: Europe

EU: Council Adopts the Pharmaceutical Package

On 28 September 2026, the Council of the European Union adopted the EU pharmaceutical package, marking another important step in the legislative process for the comprehensive reform of EU pharmaceutical legislation.
Read more
Previous
Next